552 related articles for article (PubMed ID: 24838289)
1. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
2. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials.
Greiser CM; Greiser EM; Dören M
Hum Reprod Update; 2005; 11(6):561-73. PubMed ID: 16150812
[TBL] [Abstract][Full Text] [Related]
5. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.
Yuk JS; Kim T; Cho H; Gwak G
Eur J Endocrinol; 2024 Jan; 190(1):1-11. PubMed ID: 38128117
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy and risk of epithelial ovarian cancer.
Rossing MA; Cushing-Haugen KL; Wicklund KG; Doherty JA; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2548-56. PubMed ID: 18086757
[TBL] [Abstract][Full Text] [Related]
8. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
[TBL] [Abstract][Full Text] [Related]
9. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.
Zhong GC; Liu Y; Chen N; Hao FB; Wang K; Cheng JH; Gong JP; Ding X
Hum Reprod Update; 2016 Dec; 23(1):126-138. PubMed ID: 27655589
[TBL] [Abstract][Full Text] [Related]
10. Micronized progesterone, progestins, and menopause hormone therapy.
Hipolito Rodrigues MA; Gompel A
Women Health; 2021 Jan; 61(1):3-14. PubMed ID: 32957843
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and breast cancer incidence in Korean women.
Choi E; Lee JK; Baek JK; Chung Y; Kim H; Yun BH; Seo SK
Maturitas; 2024 May; 183():107946. PubMed ID: 38412593
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
[TBL] [Abstract][Full Text] [Related]
13. The impact of micronized progesterone on breast cancer risk: a systematic review.
Stute P; Wildt L; Neulen J
Climacteric; 2018 Apr; 21(2):111-122. PubMed ID: 29384406
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ; Chen JL; Luo Y; Mathur MB; Anagnostis P; Nurmatov U; Talibov M; Zhang J; Hawrylowicz CM; Lumsden MA; Critchley H; Sheikh A; Lundbäck B; Lässer C; Kankaanranta H; Lee SH; Nwaru BI
PLoS Med; 2021 Aug; 18(8):e1003731. PubMed ID: 34339416
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
16. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
Canonico M; Plu-Bureau G; Scarabin PY
Maturitas; 2011 Dec; 70(4):354-60. PubMed ID: 22024394
[TBL] [Abstract][Full Text] [Related]
17. Menopausal Hormone Therapy Formulation and Breast Cancer Risk.
Abenhaim HA; Suissa S; Azoulay L; Spence AR; Czuzoj-Shulman N; Tulandi T
Obstet Gynecol; 2022 Jun; 139(6):1103-1110. PubMed ID: 35675607
[TBL] [Abstract][Full Text] [Related]
18. Relationship between menopausal hormone therapy and incidence of fractures in postmenopausal women.
Kim H; Kang MJ; Baek JK; Lee JK; Choi EA; Yun BH; Kim EH; Seo SK
Climacteric; 2024 Apr; 27(2):165-170. PubMed ID: 37947171
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.
Canonico M; Carcaillon L; Plu-Bureau G; Oger E; Singh-Manoux A; Tubert-Bitter P; Elbaz A; Scarabin PY
Stroke; 2016 Jul; 47(7):1734-41. PubMed ID: 27256671
[TBL] [Abstract][Full Text] [Related]
20. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
